Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension

Advances in Therapy

Volumn 28, Issue 5, 2011, Pages 427-438

  Lai, Wen Ter ^a   Park, Jeong Euy ^b   Dongre, Neelesh ^c   Wang, Jackson ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Samsung Medical Center   (South Korea)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CAG Sector of Agilent Technologies Taiwan Ltd   (Taiwan)

Author keywords

Asian; combination therapy; efficacy; hypertension; tolerability; valsartan hydrochlorothiazide single pill

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASIAN; BLOOD PRESSURE REGULATION; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIHYPERTENSIVE AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PACIFIC ISLANDS; TETRAZOLES; VALINE; YOUNG ADULT;

EID: 79958207224     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0014-4     Document Type: Article

References (23)

1. Whelton PK, Beevers DG, Sonkodi S. Strategies for improvement of awareness, treatment and control of hypertension: results of a panel discussion. J Hum Hypertens. 2004;18:563-565. (Pubitemid 39173533)
2. Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000;14:749-763.
3. Ruilope LM, Burnier M, Muszbek N, et al. Public health value of fixed-dose combinations in hypertension. Blood Press Suppl. 2008;1:5-14.
4. Volpe M, Tocci G. 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens. 2009;27(Suppl. 3):S3-11.
5. Mendis S, Abegunde D, Oladapo O, Celletti F, Nordet P. Barriers to management of cardiovascular risk in a low-resource setting using hypertension as an entry point. J Hypertens. 2004;22:59-64. (Pubitemid 38293531)
6. Dusing R, Handrock R, Klebs S, Tousset E, Vrijeno B. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009;27:894-901.
7. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77:1279-1286.
8. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. (Pubitemid 37430158)
9. Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006;7:575-581.
10. Fanestil DD, Vaughn DA, Ma L, Hyde RH, Printz MP. Thiazide diuretics normalize urinary calcium in spontaneously hypertensive male rats. Kidney Int. 1997;51:1018-1021. (Pubitemid 27186525)
11. Melby JC. Selected mechanisms of diuretic-induced electrolyte changes. Am J Cardiol. 1986; 58:1A-4A.
12. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3:72-78. (Pubitemid 34966176)
13. Black HR, Levy DG, Crikedair N, Rocha R. Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertension. 2008;2:476-483.
14. Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PDM, Zhao Y, Grosso A. Efficacy and tolerability of combiation therapy with valsartan/ hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 24;8:2303-2311.
15. Weinberger MH, Glazer RD Crikelair NA, Chiang YT. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared to monotherapy. J Hum Hypertens. 2010;24:823-830
16. Pool JL, Glazer R, Crikelair N, Levy D. The role of baseline blood pressure in guiding treatment choice. A secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double blind, placebo-controlled trial. Clin Drug Invest. 2009;29:791-802.
17. National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: www.nhlbi.nih.gov/guidelines/hypertension/ . Accessed March 14, 2011.
18. Tiwari H, Kumar A, Kulkarni SK. Prescription monitoring of anti-hypertensive drug utilization at the Panjab University Health Centre in India. Singapore Med J. 2004;45:117-120. (Pubitemid 38987107)
19. Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143-151.
20. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006; 48;846-852.
21. Tardif JC, Curnew GP, Leclerc JM, Rehel B. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4). Can J Clin Pharmacol. 2008;15:e177-e187. (Pubitemid 351838503)
22. Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:103-112.
23. Asmar R, Oparil S. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. Clin Exp Hypertens. 2010;32:499-503.